Thromb Haemost 1989; 61(03): 526-528
DOI: 10.1055/s-0038-1646628
International Committee Communications
Schattauer GmbH Stuttgart

Registry of Clinical Trials of Antithrombotic Drugs in Cancer

The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Subcommittee on Hemostasis and Malignancy
Leo R Zacharski
Dartmouth Medical School and the VA Hospital, White River Junction, Vermont, U.S.A.
,
Maria Benedetta Donati
1   The Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy
› Author Affiliations
Further Information

Publication History

Received 24 January 1989

Accepted 27 January 1989

Publication Date:
24 July 2018 (online)

 
  • References

  • 1 Torngren S, Rieger A. The influence of heparin and curable resection on the survival of colon cancer. Acta Chir Scand 1983; 149: 427-429
  • 2 Lipton A, Scialla S, Harvey H, Dixon R, Gordon R, Hamilton R, Ramsey H, Weltz M, Heckard R, White D. Adjuvant antiplatelet therapy with aspirin in colo-rectal cancer. J Med 1983; 13: 419-429
  • 3 Lipton A, Harvey H, Dixon R, Walker B, White-Hersey D, Bartholomew M, Heckard R. Adjuvant antiplatelet trials in small-cell lung and colorectal cancer. Proc 4th Eur Conf Clin Oncol 1987; 41
  • 4 Lebeau B, Chastang C. “Petites Cellules” Group. First interim analysis of a randomized clinical trial of aspirin like a platelet aggregation inhibitor in small cell lung cancer (320 patients) Bull Eur Physiopat Resp 1986; 22 Suppl (Suppl. 08) 1595
  • 5 Powles TJ, Dady PJ, Williams J, Easty GC, Coombes RC. Use of inhibitors of prostaglandin synthesis in patients with breast cancer. Adv Prostaglandin Thromboxane Res 1980; 6: 511-516
  • 6 Weppelmann B, Monkemeier D. The influence of prostaglandin antagonist on radiation therapy of carcinoma of the cervix. Gynecol Oncol 1984; 17: 196-199
  • 7 Zacharski LR, Henderson WG, Rickies FR, Forman WB, Cornell Jr CJ, Forcier RJ, Headley E, Kim S-H, O’Donnell JF, O’Dell R, Tornyos K, Kwaan HC. Effect of warfarin on survival in small cell carcinoma of the lung. VA Cooperative Study # 75 JAMA 1981; 245: 831-835
  • 8 Zacharski LR, Henderson WG, Rickies FR, Forman WB, Cornell Jr CJ, Forcier RJ, Edwards RI, Headley E, Kim S-H, O’Donnell JF, O’Dell R, Tornyos K, Kwaan HC. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon head and neck and prostate. Final report of VA Cooperative Study 75 Cancer 1984; 53: 2046-2052
  • 9 Chahinian AP, Ware JH, Zimmer B, Comis RI, Perry MC, Hirsh V, Skarin AT, Raich PC, Weiss RB, Green M, Carey RW. Update on anticoagulation with warfarin and an alternating chemotherapy in extensive small cell carcinoma of the lung (SCCL). Proc Am Soc Clin Oncol 1985; 4: 191
  • 10 Schneider B, Geser C, Feuerer W. Effect of anticoagulation treatment with RA-233 (Mopidamole) on survival in bronchial cancer. Thromb Haemostas 1987; 58: 508
  • 11 Zacharski R, Cornell CJ, Haakenson CM, Rallards HS, Crum ED, Johnson GJ, Levine J, Hong WK, O’Donnell JF, Schilsky RL, Ringemberg QS, Robert F, Spaulding MB, Tornyos K, William C, Zucker S. Effect of RA-233 (Mopidamole) on survival in carcinoma of the lung and colon. Final report of VA Cooperative Study 188 J Natl Cancer Inst 1988; 80: 9097-9141
  • 12 Tartaglia A, Goldberg JD, Berk PD, Wassermann LR. Adverse effects of antiaggregation platelet therapy in the treatment of polycythemia vera. Semin Hematol 1986; 23: 172-176
  • 13 Kessinger A, Foley JF, Lemon HM. Therapeutic management of small cell lung cancer. JAMA 1983; 250: 3188-3191
  • 14 Cantwell B, Buamah P, Harris AL. Phase I and II study of oral verapamil (VRP) and intravenous vindesine (VDN). Proc Am Soc Clin Oncol 1985; 4: 42
  • 15 Milroy R, Connery L, Banham S, Hutcheon A, MacIntyre D, Stack B. A randomized trial of verapamil in addition to chemotherapy for small cell lung cancer. Thorax 1987; 42: 209